Rock Stars Are Getting Prostate Cancer. Is Active Surveillance Enough?

By Dr. Stephen Petteruti

Another well-known musician has announced he is facing prostate cancer. Chris Holmes, former guitarist for W.A.S.P., is reportedly preparing for radiation and hormone therapy while asking fans to help cover the financial burden of his care.

I extend my best wishes to him and hope more information becomes available.

What was his PSA history? What did his imaging show? Was the disease confined to the prostate, extending beyond the capsule, or metastatic? Was hormone therapy recommended because he had symptoms and documented spread, or because it remains part of the standard treatment package?

Without those answers, it is impossible for anyone outside his medical team to determine whether active surveillance was appropriate in his case. However, his story raises a broader question that receives insufficient attention:

Why is there extensive coverage of prostate cancer treatment, yet so little discussion about men who choose not to pursue immediate intervention?

Rod Stewart, Elton John, Paul Stanley, Kenny Loggins, Andy Taylor, and several other musicians have publicly discussed prostate cancer. Their stories often focus on diagnosis, surgery, radiation, or hormone therapy.

Where are the accounts of men who opted for careful monitoring?

Statistically, it is likely that some musicians with prostate cancer are living with the disease without undergoing surgery, radiation, or hormone therapy. Yet, their experiences are seldom reported.

Perhaps statements such as “I monitor my PSA and get an annual MRI” do not generate the same media attention as declarations of “I beat cancer.” Such narratives lack the dramatic progression that the media often prefers, including major procedures, triumphant recoveries, or benefit concerts.

Instead, there is simply an individual continuing his daily life while closely monitoring his prostate health.

The term active surveillance is frequently portrayed as a reluctant compromise. Patients are often informed, “You have cancer, but we are going to watch it for now.” Subsequently, they may experience anxiety as they await each PSA result, anticipating the possibility of further biopsies. I do not consider that an effective strategy.

From Passive Surveillance to Active Management

My approach emphasizes active management. The objective is not to passively wait for adverse developments, but rather to assess whether the disease remains contained and to support the conditions that help maintain this containment.

The central question is not simply whether abnormal cells exist. The more useful question is:

Have they left the prostate?

Prostate cancer is not fatal while it remains confined within the prostate gland. The risk arises when the disease extends beyond the prostate capsule and spreads to surrounding tissues, lymph nodes, bones, or other organs. This distinction should inform the entire evaluation process.

I do not believe that any individual with an elevated PSA requires a biopsy.

PSA is a signal. It is not a diagnosis, a stage, or a prediction of how the condition will behave. PSA changes with age, inflammation, infection, ejaculation, exercise, hydration, laboratory variation, and prostate size. A single elevated result should not start a countdown to treatment.

I assess PSA trends over time and utilize the Prostate Health Index for greater specificity when necessary. I also prefer high-quality prostate MRI without gadolinium contrast to evaluate the gland, capsule, seminal vesicles, and adjacent structures.

These pieces provide a sequential picture:

• What is the PSA doing?

• How quickly is it changing?

• What does the PHI show?

• Is the MRI stable?

• Is the prostate capsule intact?

• Is there evidence of regional extension or distant spread?

Aggressiveness is determined by behavior over time. A single biopsy provides a tissue sample from one point in time, whereas sequential monitoring reveals the ongoing dynamics of the disease process.

Monitoring does not entail disregarding the internal environment in which abnormal cells develop. My patients address factors that contribute to disease progression, such as insulin resistance, inflammation, poor metabolic health, excess body fat, low muscle mass, inadequate sleep, toxic-metal burden, and nutritional deficiencies.

Depending on the patient’s stage and overall health, the plan might include nutrition, exercise, metabolic treatment, carefully selected supplements, hormone optimization, and physician-supervised repurposed medications.

The objective is not to guarantee the elimination of every abnormal prostate cell. Rather, the aim is to preserve vitality while minimizing the conditions that facilitate disease progression.

This approach is considerably more proactive than simply repeating biopsies while awaiting the necessity of conventional treatment.

Chris Holmes’ story focuses on the financial cost of prostate cancer care. Those costs are real. Hormone therapy, imaging, biopsies, radiation, travel, bloodwork, and follow-up visits add up quickly.

There is an additional cost that receives less attention.

The Physical Cost of Radiation and Hormone Therapy

Radiation carries risks to urinary, bowel, and sexual function. Hormone therapy can cause muscle loss, fatigue, cognitive changes, depression, osteoporosis, metabolic dysfunction, cardiovascular risk, and loss of sexual function.

These consequences are significant, particularly when treatment is offered to individuals whose disease may never pose a threat to their lives.

The decision-making process changes when an individual presents with symptomatic or widespread metastatic disease. Even in such cases, treatment should balance disease control with quality of life. Increased intervention does not necessarily equate to improved outcomes.

Before initiating irreversible therapy, patients should be informed about the expected outcomes, evidence regarding survival benefit, potential loss of function, and available alternatives.

Singer Montell Jordan provides a distinct and sobering example. Following his prostate cancer diagnosis, Jordan underwent a radical prostatectomy. The procedure removed his prostate, and the surgical margins were reported as clear.

He anticipated announcing to the public that he had overcome prostate cancer.

Within a year, follow-up imaging revealed cancer in his lymph nodes and the region previously occupied by his prostate. Subsequently, he received radiation and hormone therapy. In December 2025, he reported being cancer-free once more.

His experience prompts a question that men rarely encounter before surgery:

If the surgical margins were clear, how did cancer subsequently develop outside the prostate?

Removal of the prostate gland does not ensure that all cancer cells have been eliminated. Clear surgical margins indicate that cancer was not detected at the edge of the excised tissue. However, this finding does not confirm that malignant cells had not already migrated beyond the prostate.

Jordan’s experience further illustrates the importance of understanding the extent of disease prior to committing to irreversible treatment. Surgery did not conclude his treatment journey; instead, it necessitated ongoing monitoring, further imaging, radiation, and hormone therapy.

This outcome does not indicate that his initial surgery was an inappropriate decision, as insufficient clinical information is available to make that determination. However, it does demonstrate that “the prostate is gone” and “the cancer is gone” are not always synonymous.

Public figures exert significant influence over public perceptions of disease. When a musician announces a diagnosis and immediately discusses surgery, radiation, or hormone therapy, audiences may begin to view these treatments as the standard response.

The missing story is the man who says:

“My PSA changed, so I slowed down.”

“I gathered more information.”

“I looked at the trend instead of reacting to one number.”

“I used imaging to determine whether the process was contained.”

“I chose active management because I was not willing to trade my present health for an uncertain future benefit.”

This approach does not constitute denial; rather, it represents informed decision-making.

No one knows whether active management was an option for Chris Holmes. His diagnosis, stage, symptoms, and imaging have not been made public in enough detail to answer that question.

However, every individual diagnosed with prostate cancer should understand that a diagnosis does not automatically necessitate immediate treatment. There is often sufficient time to pause, gather additional information, and determine the most appropriate course based on disease characteristics, personal priorities, and risk tolerance.

Rock musicians have built their careers by challenging established norms. Similarly, individuals facing prostate cancer should feel empowered to question conventional treatment pathways.

The smartest move is not always starting treatment.

Sometimes it is refusing to be rushed.

Stephen Petteruti, DO, is a board-certified family physician with more than 35 years of clinical experience. He is the founder and medical director of Intellectual Medicine, where his work focuses on men’s health, hormone and metabolic health, preventive medicine, and long-term prostate cancer risk assessment.

Dr. Petteruti works directly with men navigating elevated PSA results, prostate imaging, biopsy recommendations, Gleason scores, and prostate cancer treatment decisions. As a family physician rather than a surgeon, he approaches these decisions through a whole-patient lens, examining long-term health, treatment risks, sexual and urinary function, metabolic health, and quality of life.

He is the author of Fight Cancer Like a Man: A Breakthrough Treatment for Prostate Cancer Without Surgery, Radiation, or Sacrificing Your Manhood and host of the Intellectual Medicine Podcast.

Learn more at www.intellectualmedicine.com and www.drstephenpetteruti.com

Follow Dr. Petteruti on Instagram and Facebook: @intellectualmedicine and @dr.stephenpetteruti

The content in this article reflects the opinions and clinical experience of Dr. Stephen Petteruti and is intended for informational and educational purposes only. It is not medical advice and should not replace guidance from your personal healthcare provider. Always consult your physician before making changes to your health regimen.